Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com       SPECIAL REPORT #21.19       Alzheimer’s disease treatments (follow up)       In a presentation to analysts, Ivan Cheung, Eisai neurology chief was confident that BAN 2401 or lecanemab would receive a fast approval by the US FDA in following […]